SIlvia Locubiche and Christian Cortés join ZeClinics Scientific Department

Under a MINECO fellowship, they will reinforce the scientific department of ZeClinics.

At ZeClinics we continue in our commitment to attract talent of excellence!

Dr. Christian Cortés, with four postdocs upon his shoulders, has got a Torres y Quevedo grant to work at ZeClinics on a project related to the development of therapies for the nonalcoholic fatty liver disease through zebrafish. Christian, trained at the University of Concepción, Chile, has developed much of his scientific work at the excellent DCEXS Pompeu Fabra University and the Whitehead Institute for Biomedical Research at MIT of Cambridge, USA. During his previous years, Christian has analyzed the ability of the hypothalamus to generate new GnRH neurons under hormonal treatment, something that has contributed to better understand why patients with Kallmann syndrome can reverse their condition after treatment with GnRH or testosterone. He has also participated in the validation of diverse zebrafish mutants through in vitro translation, something that has provided an important tool for the community that uses gene editing (CRISPR, TALEN, and ZFN). With more than a dozen publications in prestigious magazines, a great sense of humor, and a lot of optimism and desire to work, we are sure that his stay at ZeClinics will be very fruitful.

On the other hand, Silvia Locubiche, an industrial Ph.D. student, will work on the generation of GRIN mutant models in zebrafish to study the main effects of this rare disease and find a way to cure it. Graduated in Biomedicine from the University of Barcelona and Master in Neurosciences, her professional experience has focused on the study of the pathophysiology of NMDA-type glutamate receptors in neurodevelopmental diseases. Over the past two years, she has actively participated in the generation of molecular tools (last generation viral vectors, DNA constructs) and has developed cellular models for the study of central nervous system dysfunction. Her work will be in close collaboration with the group of Dr. Xavier Altafaj of the Neuropharmacology and Pain Research Group of IDIBELL. Silvia is a very smart, funny and also professional person.

We have high expectations for their work and we are completely sure that their projects will be an absolute success that will produce interesting academy-business synergies.

Welcome aboard!

Have you find this news interesting?
Let us know your opinion about it

Leave a Reply

Your email address will not be published. Required fields are marked *